US Peptide Science Research Team
October 20, 2026
ARA 290 represents a paradigm shift in peptide design—one that separates a molecule's therapeutic benefits from its liabilities. Derived from the tertiary structure of erythropoietin (EPO), this 11-amino acid linear peptide (Pyr-Glu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH, molecular weight 1257 Da) was engineered to activate only the innate repair receptor (IRR) while avoiding EPO's thrombotic and hematopoietic complications. Understanding what is a peptide and how selective receptor agonism works is foundational to appreciating ARA 290's mechanistic innovation.
While recombinant EPO has been widely used clinically for anemia treatment, its off-target effects on erythropoietin receptor (EPOR) signaling create safety constraints. ARA 290 mimics the spatial configuration of EPO's B-helix domain—the region that interacts specifically with the IRR—without binding to EPOR2. This selectivity unlocks a "master switch" for anti-inflammatory and tissue repair cascades, positioning ARA 290 as a prototype for peptide therapy applications beyond traditional endocrine replacement.
The innate repair receptor is a heteromeric complex composed of the erythropoietin receptor and the β-common (CD131) receptor. Upon IRR activation, cells initiate coordinated anti-inflammatory signaling and tissue protection programs. pubmed.ncbi.nlm.nih.gov research demonstrates that IRR engagement triggers locally-produced hyposialated tissue repair factors, distinct from the systemic hematopoietic cascade triggered by classical EPO signaling.
In neuropathic pain states, peripheral nerve injury upregulates IRR expression in the spinal cord, where it modulates the neurogenic inflammatory response. Preclinical studies using spared nerve injury models in rats revealed that ARA 290 dose-dependently suppressed spinal microglia activation (measured by iba-1 immunoreactivity) over a 20-week observation period. pmc.ncbi.nlm.nih.gov data showed that animals receiving 30 μg/kg ARA 290 did not exhibit the increased microglia reactivity observed in vehicle-treated controls, suggesting a mechanistic link between central inflammation suppression and pain symptom relief.
Recent 2025 research published in the European Journal of Pharmacology identified NLRP3 inflammasome inhibition in Schwann cells following sciatic nerve injury as a downstream mechanism. This pathway—whereby ARA 290 suppresses pyroptotic signaling in myelin-producing cells—explains both acute pain relief and long-term nerve regeneration observed in clinical cohorts.
Source research
Researchers: Dahan A, Brines M, Niesters M, Cerami A, van Velzen M
Pain Rep, 2016 · DOI 10.1097/PR9.0000000000000566
ARA 290 exhibits rapid pharmacokinetic clearance optimized for receptor engagement. Following subcutaneous administration, the peptide achieves an elimination half-life of approximately 20 minutes; intravenous injection yields a 2-minute half-life. This rapid kinetics reflects quick tissue penetration and target engagement. Importantly, animal studies confirm that ARA 290 crosses the blood–brain barrier, enabling IRR activation at both central (spinal cord, brain) and peripheral sites—a critical advantage for neuropathic pain syndromes with mixed central sensitization and peripheral nerve pathology components.
pmc.ncbi.nlm.nih.gov published two randomized, placebo-controlled Phase 2 trials in sarcoidosis patients with small fiber neuropathy (SFN). The first trial (n=22) administered intravenous ARA 290 2 mg three times weekly for one month, with 3-month follow-up. Primary endpoints included pain intensity (Brief Pain Inventory), autonomic and neuropathic symptom burden (Small Fiber Neuropathy Screening List), and quality of life (RAND-36).
While pain intensity scores declined similarly in both ARA 290 and placebo arms (−2.1 vs. −2.3 points), ARA 290 produced substantially greater improvements in the SFNSL composite score at week 4, with 83% of treated patients achieving 1–5 point reductions versus 60% in placebo (and 42% achieving >15 point reductions vs. 0% placebo). Quality-of-life metrics improved significantly with ARA 290. Crucially, an open-label proof-of-concept study preceding these trials noted that after three intravenous injections over one week, pain relief peaked at 40% reduction in sarcoidosis patients (baseline pain score 7.1) with no reported adverse events.
Corneal confocal microscopy revealed that 28 days of ARA 290 treatment initiated regrowth of small nerve fibers in the cornea—objective evidence of tissue regeneration—though epididermal nerve fiber density did not increase within the trial timeframe.
A separate randomized controlled trial enrolled 48 type 2 diabetes patients with moderate-to-severe SFN-induced chronic pain. Participants received daily subcutaneous ARA 290 4 mg or placebo for 28 days. Results paralleled those in sarcoidosis: significant improvements in neuropathic pain and autonomic symptoms, coupled with an increase in corneal nerve fiber density (CNFD) in patients with baseline CNFD reduction. Notably, ARA 290 treatment produced measurable improvements in HbA1C and lipid profiles during both the active treatment phase and the 56-day follow-up period—suggesting that IRR activation may modulate glucose homeostasis and lipid metabolism independently of weight loss.
No significant adverse effects were reported across either patient population, supporting the safety profile of selective IRR agonism versus non-selective EPO analogs.
Beyond clinical trials, pmc.ncbi.nlm.nih.gov published a mechanistic study in the rat spared nerve injury model. Forty-two female Sprague-Dawley rats received intraperitoneal ARA 290 at varying doses on days 1, 3, 6, 8, and 10 post-injury. Mechanical allodynia was significantly reduced up to 20 weeks at all doses; cold allodynia suppression was significant across all treatment groups through the 20-week endpoint.
Critically, animals treated with the higher dose did not develop the widespread spinal microglia activation (elevated iba-1 immunoreactivity across multiple spinal cord segments) observed in vehicle controls at 20 weeks. This dose-dependent suppression of microglial reactivity without changes in astrocyte response (GFAP immunoreactivity) suggests a selective anti-inflammatory mechanism targeting innate immune cells in the central nervous system.
Research examining ARA 290 in experimental autoimmune neuritis—a rodent model of acute inflammatory demyelinating polyneuropathy—demonstrated that exogenous ARA 290 intervention significantly improved disease recovery, enhanced nerve regeneration, and promoted remyelination. journals.plos.org These findings extend the therapeutic window beyond chronic neuropathies to acute inflammatory nerve injury, broadening the potential disease indications for IRR-targeted peptide therapy.
The development of ARA 290 and related IRR-selective agonists (such as carbamylated EPO) emerged from the recognition that broad EPO receptor signaling carries unacceptable thrombotic and hematopoietic risks in chronic pain populations. By selectively engaging the IRR without EPOR2 binding, ARA 290 avoids polycythemia, thromboembolism, and hypertension—side effects that have historically limited EPO's use in non-anemic indications. This selectivity represents a fundamental advance in peptide design: the separation of a natural hormone's therapeutic activity from its toxicity through rational structure-based engineering.
As of early 2026, ARA 290 remains in clinical development. Published Phase 2 data support efficacy in SFN-related pain across multiple etiologies (sarcoidosis, type 2 diabetes) and demonstrate objective markers of nerve fiber regeneration. Ongoing Phase 2b and Phase 3 trials are evaluating longer-term treatment regimens, additional neuropathic pain indications (including HIV-associated neuropathy and chemotherapy-induced peripheral neuropathy), and the durability of metabolic benefits observed in diabetic cohorts.
The rapid expansion of IRR-targeting research reflects a broader appreciation for innate repair mechanisms as therapeutic targets. Future investigations may explore ARA 290 in ischemic stroke, myocardial infarction, and other acute tissue injury states where rapid anti-inflammatory reprogramming could limit secondary damage. The peptide's ability to cross the blood–brain barrier and activate central IRRs also raises questions about potential applications in neurodegenerative and neuroimmune conditions, though such indications remain investigational.
ARA 290 exemplifies modern peptide engineering: a rational derivation from an existing hormone that preserves therapeutic benefit while eliminating off-target liabilities. Clinical evidence demonstrates meaningful pain reduction, autonomic symptom improvement, and objective nerve regeneration in small fiber neuropathy patients without significant adverse effects. Preclinical mechanistic studies link these clinical outcomes to suppression of spinal microglial activation and NLRP3 inflammasome signaling, establishing a plausible biological rationale for IRR-mediated tissue repair. As peptide therapy continues to expand as a research domain, ARA 290 stands as a proof-of-concept for selective receptor agonism and a model for translating basic immunology into clinical benefit.
pubmed.ncbi.nlm.nih.gov – Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
pmc.ncbi.nlm.nih.gov – Targeting the innate repair receptor to treat neuropathy (comprehensive review of ARA 290 mechanism and clinical trials).
pmc.ncbi.nlm.nih.gov – ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.
doi.org – ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in Schwann cells after sciatic nerve injury (European Journal of Pharmacology, 2025).
journals.plos.org – Erythropoietin-Derived Nonerythropoietic Peptide effects in experimental autoimmune neuritis.